SLC5A2 and type 2 diabetes mellitus: In large-scale postmarketing randomized cardiovascular outcome trials (CVOTs), sodium-glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated a cardiorenal protective effect in patients with T2D and established cardiovascular or kidney conditions.3,4,5,6 These benefits have been reproduced in real-world evidence studies, which encompass a patient population with a broader spectrum of cardiovascular risk as seen in clinical practice.7,8 However, it is still unclear whether patients with different levels of hyperglycemia can similarly benefit from the use of SGLT2i.